The chemical name **2-(4-methoxyphenyl)-N-(phenylmethyl)-N-propan-2-ylacetamide** is a mouthful, so it's easier to understand its importance by breaking it down and understanding its structure and potential uses.
**Let's analyze the name:**
* **2-(4-methoxyphenyl):** This part indicates a benzene ring with a methoxy group (CH3O-) at the 4th position and attached to the main structure at the 2nd position.
* **N-(phenylmethyl):** This indicates a benzyl group (C6H5CH2-) attached to a nitrogen atom.
* **N-propan-2-yl:** This indicates an isopropyl group (CH3CH(CH3)-) also attached to the same nitrogen atom.
* **acetamide:** This tells us the molecule is an amide with an acetyl group (CH3CO-) attached to the nitrogen.
**Putting it all together, the molecule is:**
* A **complex amide** with a benzene ring, a methoxy group, a benzyl group, and an isopropyl group. This combination of functional groups gives it potential for biological activity.
**Importance in Research:**
* **Potential for Pharmaceutical Applications:** The molecule's structure suggests it could interact with biological targets, making it potentially interesting for drug development. The specific activity would depend on the exact details of its interactions, which need to be investigated through further research.
* **Chemical Synthesis:** The complex structure of this compound presents a challenge for organic chemists. Its synthesis could be used to develop new synthetic methods, improve reaction conditions, or study the reactivity of these functional groups.
* **Material Science:** The presence of aromatic rings and the potential for intermolecular interactions could make this compound useful in materials science for applications like polymer synthesis or as a component in new materials with unique properties.
**It's crucial to remember that without specific research on this molecule, its exact importance remains unknown.** The information above is based on the structural features and their potential applications in different research fields.
To understand the true importance of this molecule, scientists would need to conduct research, such as:
* **Biological Activity Studies:** Testing its effects on cells, tissues, or organisms to identify any potential therapeutic or toxicological properties.
* **Synthesis and Characterization:** Developing a reliable synthetic route and determining the molecule's physical and chemical properties.
* **Structure-Activity Relationship Studies:** Examining how structural modifications affect its activity, which can guide further development.
In conclusion, 2-(4-methoxyphenyl)-N-(phenylmethyl)-N-propan-2-ylacetamide has a structure that suggests potential for various research applications. However, its true importance and utility need to be further explored through focused research efforts.
ID Source | ID |
---|---|
PubMed CID | 755425 |
CHEMBL ID | 1359845 |
CHEBI ID | 119978 |
Synonym |
---|
HMS1582P09 |
smr000503171 |
MLS001183815 |
OPREA1_233186 |
AO-365/11164426 |
n-benzyl-n-isopropyl-2-(4-methoxyphenyl)acetamide |
n-benzyl-2-(4-methoxyphenyl)-n-(propan-2-yl)acetamide |
STK182894 |
CHEBI:119978 |
AKOS001063096 |
n-benzyl-2-(4-methoxyphenyl)-n-propan-2-ylacetamide |
HMS2828L10 |
Z56983838 |
CHEMBL1359845 |
Q27207763 |
2-(4-methoxyphenyl)-n-(phenylmethyl)-n-propan-2-ylacetamide |
SR-01000205937-1 |
sr-01000205937 |
349093-60-3 |
DTXSID801325548 |
Class | Description |
---|---|
acetamides | Compounds with the general formula RNHC(=O)CH3. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.9466 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 31.6228 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 20.3375 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |